TY - JOUR
T1 - Basic and clinical studies on tazobactam/piperacillin in the surgical field
AU - Yura, Jiro
AU - Shinagawa, Nagao
AU - Ishikawa, Shu
AU - Mizuno, Akira
AU - Mashita, Keiji
AU - Ishihara, Hiroshi
AU - Hisada, Masazumi
AU - Fukuhara, Tomokatsu
AU - Tachi, Yoshimasa
AU - Tsuruga, Nobuatsu
AU - Ito, Akitoshi
AU - Hori, Keiichi
AU - Okada, Hideya
AU - Miyake, Takashi
AU - Suzuki, Tatsuya
AU - Iwai, Akihiko
AU - Mizuno, Hiroshi
AU - Hayakawa, Tetsushi
AU - Okada, Yuji
AU - Kimura, Shouji
AU - Suzuki, Ichiya
AU - Nakamura, Akishige
AU - Tanabe, Katsuhiko
AU - Yamagishi, Yota
PY - 1994
Y1 - 1994
N2 - We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), an injectable antibiotic which is a combination of piperacillin (PIPC) and tazobactam (TAZ), a newly developed β-lactamase inhibitor, in the field of surgery. The following results were obtained. 1) Delivery into bile: Concentrations of PIPC, TAZ and desethyl-piperacillin (DEt-PIPC) in bile were measured in a postoperative patient with gall stone disease after intravenous drip infusion of TAZ/PIPC at 2.5 g. The peak levels in bile were 256 μg/ml, 9.98 μg/ml and 1340 μg/ml, respectively. 2) Clinical evaluation: 24 patients with surgical infections were treated with TAZ/PIPC. Clinical efficacy was excellent in 10 cases, good in 10, fair in 2 and poor in 2, the overall efficacy rate being 83.3%. Bacteriological response was observed as eradicated in 12 cases, partially eradicated in 1, replaced in 1 and unchanged in 4, resulting in a 72.2% eradication rate. No adverse reactions were observed, and abnormal changes in laboratory findings appeared in three patients.
AB - We performed basic and clinical studies on tazobactam/piperacillin (TAZ/PIPC), an injectable antibiotic which is a combination of piperacillin (PIPC) and tazobactam (TAZ), a newly developed β-lactamase inhibitor, in the field of surgery. The following results were obtained. 1) Delivery into bile: Concentrations of PIPC, TAZ and desethyl-piperacillin (DEt-PIPC) in bile were measured in a postoperative patient with gall stone disease after intravenous drip infusion of TAZ/PIPC at 2.5 g. The peak levels in bile were 256 μg/ml, 9.98 μg/ml and 1340 μg/ml, respectively. 2) Clinical evaluation: 24 patients with surgical infections were treated with TAZ/PIPC. Clinical efficacy was excellent in 10 cases, good in 10, fair in 2 and poor in 2, the overall efficacy rate being 83.3%. Bacteriological response was observed as eradicated in 12 cases, partially eradicated in 1, replaced in 1 and unchanged in 4, resulting in a 72.2% eradication rate. No adverse reactions were observed, and abnormal changes in laboratory findings appeared in three patients.
UR - https://www.scopus.com/pages/publications/0028076194
UR - https://www.scopus.com/pages/publications/0028076194#tab=citedBy
U2 - 10.11250/chemotherapy1953.42.Supplement2_581
DO - 10.11250/chemotherapy1953.42.Supplement2_581
M3 - Article
AN - SCOPUS:0028076194
SN - 0009-3165
VL - 42
SP - 581
EP - 589
JO - CHEMOTHERAPY
JF - CHEMOTHERAPY
ER -
